羟基脲改善镰状细胞贫血患儿脑氧饱和度
本研究基于TREAT试验,分析羟基脲对镰状细胞贫血(SCA)患儿脑组织氧饱和度(SCT O2)的影响。新队列55例起始羟基脲时中位年龄12个月,基线SCT O2均值65%(95%CI 58-72%),治疗2年后显著升至72%(95%CI 65-79%,p<.001)。长期用药队列(中位年龄9.6岁)SCT O2正常且2年内稳定,两队列均高于已发表未治疗患者数据。
要点
- 羟基脲治疗2年可显著提高SCA患儿SCT O2,提示神经生理保护。
- 长期羟基脲治疗者SCT O2维持正常且2年内稳定。
- 脑氧测定是无创评估脑血管病理的补充工具。
核心结论
- 羟基脲提示可保护SCA患儿免于未治疗者出现的神经生理改变。
研究设计与样本
- 分析TREAT试验(NCT02286154)中起始个体化剂量羟基脲的新队列(n=55,中位起始年龄12个月)和既往用药的老队列(中位年龄9.6岁)。
- 基线和每年进行脑氧测定。
主要发现
- 新队列基线SCT O2均值65%(95%CI 58-72%),2年后显著升至72%(95%CI 65-79%,p<.001)。
- 老队列入组时SCT O2均值66%(95%CI 58-74%),2年内保持稳定。
- 两队列SCT O2均显著高于已发表的主要为未治疗SCA患者的数据。
临床怎么用
- 脑氧测定可作为无创手段补充常规影像评估SCA脑血管病理。
- 羟基脲治疗可能有助于维持SCA患儿正常脑氧饱和度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurologic complications are common in patients with sickle cell anemia (SCA), but conventional tools such as MRI and transcranial Doppler ultrasonography (TCD) do not fully assess cerebrovascular pathology. Cerebral tissue oximetry measures mixed oxygen saturation in the frontal lobes (SCT O2 ) and provides early prognostic information about tissue at risk of ischemic injury. Untreated patients with SCA have significantly lower SCT O2 than healthy controls that declines with age. Hydroxyurea is effective in preventing many SCA-related complications, but the degree to which it preserves normal neurophysiology is unclear. We analyzed participants enrolled in the Therapeutic Response Evaluation and Adherence Trial (TREAT, NCT02286154), which enrolled participants initiating hydroxyurea using individualized dosing (new cohort) and those previously taking hydroxyurea (old cohort) and was designed to monitor the long-term benefits of hydroxyurea. Cerebral oximetry was performed at baseline and annually. For the new cohort (median starting age = 12 months, n = 55), mean baseline SCT O2 was normal before starting hydroxyurea (mean 65%, 95% CI 58-72%) and significantly increased after 2 years (mean 72%, 95% CI 65-79%, p < .001). The SCT O2 for patients receiving long-term hydroxyurea (median age = 9.6 years) was normal at study entry (mean 66%, 95% CI 58-74%) and remained stable across 2 years. Both cohorts had significantly higher SCT O2 than published data from predominantly untreated SCA patients. Cerebral oximetry is a non-invasive method to assess cerebrovascular pathology that complements conventional imaging. Our results indicate that hydroxyurea suggests protection against neurophysiologic changes seen in untreated SCA.
引用
- Karkoska K, Quinn CT, Niss O, et al. Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia. Am J Hematol. 2021. PMID: 33534136. doi:10.1002/ajh.26120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。